Skip to main content

Advertisement

Log in

Delayed gastric emptying: Whom to test, how to test, and what to do

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Gastroparesis, or delayed gastric emptying, is a common cause of chronic nausea and vomiting as seen in a gastroenterology practice. Diabetic, postsurgical, and idiopathic causes remain the three most common forms of gastroparesis. In addition to nausea and vomiting, symptoms of gastroparesis may include early satiety, postprandial fullness, and abdominal pain. Physiologic changes that may explain symptoms in patients with gastroparesis, in addition to delayed gastric emptying, include impaired fundic accommodation, antral hypomotility, gastric dysrhythmias, pylorospasm, and perhaps visceral hypersensitivity. Diagnosis of gastroparesis is best determined using a radioisotope-labeled solid meal with scintigraphic imaging for at least 2 hours, and preferably 4 hours, postprandially. Most commonly, a 99mTc sulfur colloid-labeled egg sandwich with imaging at 0, 1, 2, and 4 hours is used. Extension of the gastric emptying test to 4 hours improves the accuracy of the test, but unfortunately, this is not commonly performed at many centers. Emptying of liquids remains normal until the late stages of gastroparesis and is less useful. The aims of treatment should be to control symptoms and maintain adequate nutrition and hydration. Patients should be advised to eat small meals and to limit their intake of fat and fiber. Additional dietary recommendations may include increasing caloric intake in the form of liquids. For diabetic patients, control of blood glucose levels is important, as symptom exacerbation is frequently associated with poor glycemic control. Specific treatment often begins with metoclopramide, 10 mg, up to four times daily, after a discussion of possible side effects with the patient. An antiemetic agent, such as prochlorperazine, 5 to 10 mg orally or 25 mg by suppository, can be added on an as-needed basis every 4 to 6 hours to control nausea. If these antiemetic medications are not effective, or if side effects develop, orally dissolving ondansetron, 8 mg every 8 to 12 hours, can be tried on an as-needed basis. If this regimen is unsuccessful, then alternative prokinetic agents—erythromycin, 125 mg, or tegaserod, 6 mg, prior to meals—can be tried. For cases refractory to these treatments, referral to a center with US Food and Drug Administration permission to use domperidone should be considered. Alternatively, symptom modulators such as low-dose tricyclic antidepressants can be tried to reduce symptoms, but these do not improve gastric emptying. In patients for whom all medical therapy fails, other options that are tried at experienced centers include the injection of botulinum toxin into the pylorus, placement of a feeding jejunostomy, and/or placement of a gastric electrical stimulator.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Soykan I, Sivri B, Sarosiek I, et al.: Demography, clinical characteristics, psychological profiles, treatment and long-term follow-up of patients with gastroparesis. Dig Dis Sci 1998, 43:2398–2404.

    Article  PubMed  CAS  Google Scholar 

  2. Frank JW, Saslow SB, Camilleri M, et al.: Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology 1995, 109:755–765.

    Article  PubMed  CAS  Google Scholar 

  3. Kong MF, Horowitz M, Jones KL, et al.: Natural history of diabetic gastroparesis. Diabetes Care 1998, 22:503–507.

    Article  Google Scholar 

  4. He CL, Soffer EE, Ferris CD, et al.: Loss of interstitial cells of Cajal and inhibitory innervation in insulindependent diabetes. Gastroenterology 2001, 121:427–434.

    Article  PubMed  CAS  Google Scholar 

  5. Sarnelli G, Caenepeel P, Geypens B, et al.: Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol 2003, 98:783–788.

    Article  PubMed  Google Scholar 

  6. Jebbink RJA, Samsom M, Bruijs PPM, et al.: Hyperglycemia induces abnormalities of gastric myoelectrical activity in patients with type 1 diabetes mellitus. Gastroenterology 1994, 107:1390–1397.

    PubMed  CAS  Google Scholar 

  7. Hasler WL, Soudah HC, Dulai G, Owyang C: Mediation of hyperglycemia-evoked gastric slow-wave dysrhythmias by endogenous prostaglandins. Gastroenterology 1995, 108:727–736.

    Article  PubMed  CAS  Google Scholar 

  8. Lemann M, Dederding JP, Flourie B, et al.: Abnormal perception of visceral pain in response to gastric distension in chronic idiopathic dyspepsia. Dig Dis Sci 1991, 36:1249–1254.

    Article  PubMed  CAS  Google Scholar 

  9. Hoogerwerf WA, Pasricha PJ, Kalloo AN, Schuster MM: Pain: the overlooked symptom in gastroparesis. Am J Gastroenterol 1999, 94:1029–1033.

    Article  PubMed  CAS  Google Scholar 

  10. Kim DY, Myung SJ, Camilleri M: Novel testing of human gastric motor and sensory functions: rationale, methods, and potential applications in clinical practice. Am J Gastroenterol 2000, 95:3365–3373.

    Article  PubMed  CAS  Google Scholar 

  11. Guo JP, Maurer AH, Fisher RS, Parkman HP: Extending gastric emptying scintigraphy from two to four hours detects more patients with gastroparesis. Dig Dis Sci 2001, 46:24–29.

    Article  PubMed  CAS  Google Scholar 

  12. Datz FL, Christian PE, Moore J: Gender-related differences in gastric emptying. J Nucl Med 1987, 28:1204–1207.

    PubMed  CAS  Google Scholar 

  13. Parkman HP, Schwartz SS: Esophagitis and other gastrointestinal disorders associated with diabetic gastroparesis. Arch Intern Med 1987, 147:1477–1480.

    Article  PubMed  CAS  Google Scholar 

  14. Parkman HP, Harris AD, Krevsky B, et al.: Gastroduodenal motility and dysmotility: update on techniques available for evaluation. Am J Gastroenterol 1995, 90:869–892.

    PubMed  CAS  Google Scholar 

  15. Thomforde GM, Camilleri M, Phillips SF, Forstrom LA: Evaluation of an inexpensive screening scintigraphic test of gastric emptying. J Nucl Med 1995, 36:93–96.

    PubMed  CAS  Google Scholar 

  16. Choi MG, Camilleri M, Burton DD, et al.: Reproducibility and simplification of 13C-octanoic acid breath test for gastric emptying of solids. Am J Gastroenterol 1998, 93:92–98.

    Article  PubMed  CAS  Google Scholar 

  17. Bromer MQ, Kantor SB, Wagner DA, et al.: Simultaneous measurement of gastric emptying with a simple muffin meal using [13C] octanoate breath test and scintigraphy in normal subjects and patients with dyspeptic symptoms. Dig Dis Sci 2002, 47:1657–1663.

    Article  PubMed  Google Scholar 

  18. Ghoos YF, Maes BD, Geypens BJ, et al.: Measurement of gastric emptying rate of solids by means of a carbonlabeled octanoic acid breath test. Gastroenterology 1993, 104:1640–1647.

    PubMed  CAS  Google Scholar 

  19. Soffer E, Thongsawat S: Clinical value of duodenojejunal manometry. Its usefulness in diagnosis and management of patients with gastrointestinal symptoms. Dig Dis Sci 1996, 41:859–863.

    Article  PubMed  CAS  Google Scholar 

  20. Mearin F, Camilleri M, Malagelada JR: Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology 1986, 90:1919–1925.

    PubMed  CAS  Google Scholar 

  21. Camilleri M, Brown ML, Malagelada JR: Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology 1986, 91:94–99.

    PubMed  CAS  Google Scholar 

  22. Friedenberg FK, Parkman HP: Management of delayed gastric emptying. Clin Gastroenterol Hepatol 2005, 3:642–646. Recent review of clinical management of a patient with diabetic gastroparesis that provides an algorithm for treatment.

    Article  PubMed  Google Scholar 

  23. Lehmann R, Honegger RA, Feinle C, et al.: Glucose control is not improved by accelerating gastric emptying in patients with type 1 diabetes mellitus and gastroparesis. A pilot study with cisapride as a model drug. Exp Clin Endocrinol Diabetes 2003, 111:255–261.

    Article  PubMed  CAS  Google Scholar 

  24. Petiakis IE, Vrachassotakis N, Sciacca V, et al.: Hyperglycemia attenuates erythromycin-induced acceleration of solid phase gastric emptying in idiopathic and diabetic gastroparesis. Scand J Gastroenterol 1999, 34:396–403.

    Article  Google Scholar 

  25. Brownlee M, Kroopf SS: Metoclopramide for gastroparesis diabeticorum. N Engl J Med 1974, 291:1257–1258.

    PubMed  CAS  Google Scholar 

  26. Perkel MS, Moore C, Hersh T, Davidson ED: Metoclopramide therapy in patients with delayed gastric emptying. Dig Dis Sci 1979, 24:662–666.

    Article  PubMed  CAS  Google Scholar 

  27. McCallum RW, Ricci DA, Rakatansky H, et al.: A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care 1983, 6:463–467.

    Article  PubMed  CAS  Google Scholar 

  28. Ganzini L, Casey DE, Hoffman WF, McCall AL: The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993, 153:1469–1475.

    Article  PubMed  CAS  Google Scholar 

  29. Miller LG, Jankovic J: Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med 1989, 149:2486–2492.

    Article  PubMed  CAS  Google Scholar 

  30. Lata PF, Pigarelli DL: Chronic metoclopramide therapy for diabetic gastroparesis. Ann Pharmacother 2003, 37:122–126.

    Article  PubMed  CAS  Google Scholar 

  31. Peeters TL: Erythromycin and other macrolides as prokinetic agents. Gastroenterology 1993, 105:1886–1899.

    PubMed  CAS  Google Scholar 

  32. Patterson D, Abell T, Rothstein R, et al.: A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999, 94:1230–1234.

    PubMed  CAS  Google Scholar 

  33. Watts GF, Armitage M, Sinclair J, Hill JD: Treatment of diabetic gastroparesis with oral domperidone. Diabetic Med 1985, 2:491–492.

    Article  PubMed  CAS  Google Scholar 

  34. Jones MP: Access options for withdrawn motility-modifying agents. Am J Gastroenterol 2002, 97:2184–2188.

    Article  PubMed  Google Scholar 

  35. DiBaise JK, Quigley EMM: Efficacy of prolonged administration of intravenous erythromycin in an ambulatory setting as treatment of severe gastroparesis. J Clin Gastroenterol 1999, 28:131–134.

    Article  PubMed  CAS  Google Scholar 

  36. Maganti K, Onyemere K, Jones MP: Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol 2003, 98:259–263.

    PubMed  CAS  Google Scholar 

  37. Erbas T, Varoglu E, Erbas B, et al.: Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care 1993, 16:1511–1514.

    Article  PubMed  CAS  Google Scholar 

  38. Di Stefano M, Vos R, Janssens J, Tack JF: Effect of tegaserod, a 5-HT4 receptor partial agonist, on interdigestive and postprandial gastrointestinal motility in healthy volunteers [abstract]. Gastroenterology 2003, 124:A163.

    Article  Google Scholar 

  39. Degen L, Matzinger D, Merz M, et al.: Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001, 15:1745–1751.

    Article  PubMed  CAS  Google Scholar 

  40. Tougas G, Chen Y, Luo D, et al.: Tegaserod improves gastric emptying in patients with gastroparesis and dyspeptic symptoms [abstract]. Gastroenterology 2003, 124:A54-A68.

    Article  Google Scholar 

  41. Bromer MQ, Friedenberg F, Miller LS, et al.: Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest Endosc 2005, 61:833–839.

    Article  PubMed  Google Scholar 

  42. Miller LS, Szych GA, Kantor SB, et al.: Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol 2002, 97:1653–1660.

    Article  PubMed  CAS  Google Scholar 

  43. Friedenberg F, Gollamudi S, Parkman HP: Review: the use of botulinum toxin for the treatment of gastrointestinal motility disorders. Dig Dis Sci 2004, 2:165–175. A thorough review of the GI uses of botulinum toxin.

    Article  Google Scholar 

  44. Hotokezaka M, Adams RB, Miller AD, et al.: Laparoscopic percutaneous jejunostomy for long term enteral access. Surg Endosc 1996, 10:1008–1011.

    Article  PubMed  CAS  Google Scholar 

  45. Abell T, McCallum R, Hocking M, et al.: Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology 2003, 125:421–428. The largest controlled trial to date on the use of the gastric stimulator.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Friedenberg, F.K., Parkman, H.P. Delayed gastric emptying: Whom to test, how to test, and what to do. Curr Treat Options Gastro 9, 295–304 (2006). https://doi.org/10.1007/s11938-006-0011-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-006-0011-x

Keywords

Navigation